These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28732654)

  • 1. Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature.
    Dumbrill JL; Moulton CD
    Prim Care Diabetes; 2018 Feb; 12(1):51-58. PubMed ID: 28732654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
    Dawwas GK; Smith SM; Park H
    Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors.
    Darsalia V; Larsson M; Klein T; Patrone C
    Cardiovasc Diabetol; 2018 Feb; 17(1):32. PubMed ID: 29466979
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety trials of incretin-based drugs: What do they mean?
    Yabe D; Seino Y
    J Diabetes Investig; 2017 May; 8(3):272-276. PubMed ID: 27612317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular Effects of Incretin-Based Therapies and Their Therapeutic Potential].
    Tyurenkov IN; Bakulin DA; Kurkin DV; Volotova EV
    Vestn Ross Akad Med Nauk; 2017; 72(1):66-75. PubMed ID: 29308856
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The journey to understanding incretin systems: Theory, practice and more theory.
    Yabe D; Kuwata H; Seino Y
    J Diabetes Investig; 2019 Sep; 10(5):1171-1173. PubMed ID: 31361402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of incretin-based therapy in hospitalized patients with type 2 diabetes.
    Gracia-Ramos AE
    J Diabetes Investig; 2020 Mar; 11(2):508-509. PubMed ID: 31529777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin-based medications for type 2 diabetes: an overview of reviews.
    Gamble JM; Clarke A; Myers KJ; Agnew MD; Hatch K; Snow MM; Davis EM
    Diabetes Obes Metab; 2015 Jul; 17(7):649-58. PubMed ID: 25772666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
    Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health.
    Egger A; Kraenzlin ME; Meier C
    Curr Osteoporos Rep; 2016 Dec; 14(6):345-350. PubMed ID: 27709509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
    Panchapakesan U; Mather A; Pollock C
    Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip.
    Luconi M; Cantini G; Ceriello A; Mannucci E
    Int J Cardiol; 2017 Aug; 241():302-310. PubMed ID: 28285800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of incretin-based therapies on renal function.
    Tsimihodimos V; Elisaf M
    Eur J Pharmacol; 2018 Jan; 818():103-109. PubMed ID: 29066413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies in 2021 - Current status and perspectives for the future.
    Rizzo M; Nauck MA; Mantzoros CS
    Metabolism; 2021 Sep; 122():154843. PubMed ID: 34333000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.